The impact of the new ‘guard rails’ for price negotiations on pharmaceutical expenditure in Germany: A simulation exercise and retrospective analysis

Despite the significant potential savings identified in this analysis, the actual annual savings are inconsistent and challenging to predict as they largely depend on the number of new product launches and the extent of their added benefit demonstrated. The application of the 'guard rails' remains rather complex and legally ambiguous, suggesting that further contentious discussions are likely in the future.